Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
March 16 2023 - 7:31AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune
disease, today announced preclinical data at the 2023 American
Association for Cancer Research (AACR) Annual Meeting in Orlando,
Florida, from the company’s GADLEN platform.
“We are pleased to share pre-clinical data demonstrating that
the CD20-targeted GADLEN efficiently directs small numbers of human
Vγ9Vδ2 T cells to serially kill greater than 99% of human B cells
in a humanized mouse model,” said Taylor Schreiber, M.D.,
Ph.D., Chief Executive Officer of Shattuck. “These data led to the
first study of a GADLEN compound in non-human primates, where once
again treatment with a CD20-targeted GADLEN directed low
frequencies of endogenous Vγ9Vδ2 T cells to eliminate CD20 positive
B cells with a rapid kinetic. Importantly, the GADLEN compound was
well tolerated in non-human primates up to the highest administered
dose of 25 mg/kg, without evidence of cytokine release syndrome or
other toxicities, potentially providing differentiation from
CD3-directed T cell engagers. These data underlie our enthusiasm to
advance a GADLEN product candidate into the clinic designed for the
treatment of antibody-mediated autoimmune diseases.”
Details of the presentations are as follows:
Abstract title: Rapid Serial Killing of Target
Cells by Vγ9Vδ2 T Cells in Cynomolgus Macaques and
Humanized Mice Treated with a CD20-Directed Heterodimeric
Butyrophilin 2A1/3A1 Fusion Protein
Shattuck to present preclinical data highlighting the potential
of a CD20-targeted GADLEN to direct Vγ9Vδ2 T cells to kill B
cells in vivo in cynomolgus macaques and a humanized mouse
model.
Shattuck’s bispecific GADLEN compound, which contains
heterodimeric BTN2A1 and BTN3A1 extracellular domains fused via an
inert Fc linker to an scFv domain targeting CD20 tumor-antigens,
demonstrated an ability to rapidly deplete human and cynomolgus B
cells in a dose-dependent manner.
Location: Orange County Convention Center,
Orlando, FloridaPresenter: Dr. Anne Lai,
Ph.D., Associate Director R&D, Shattuck
LabsSession: Immunomodulatory Agents and
Interventions 1Date/Time: Monday, Apr 17, 2023,
9:00 AM - 12:30 PMLocation: Section
23Poster Board Number: 19Abstract
Presentation Number: 1815
Additional meeting information can be found on the AACR website,
https://www.aacr.org. The poster will be available under Posters on
the Company’s website shortly after the event
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s lead SL-172154
(SIRPα-Fc-CD40L) program, which is designed to block the CD47
immune checkpoint and simultaneously agonize the CD40 pathway, is
being evaluated in multiple Phase 1 trials. Additionally, the
company is advancing a proprietary Gamma Delta T Cell Engager,
GADLEN™, platform, which is designed to bridge gamma delta T cells
to tumor antigens for the treatment of patients with cancer.
Shattuck has offices in both Austin, Texas and Durham, North
Carolina. For more information, please visit:
www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor & Media Contact: Conor
RichardsonVice President of Investor RelationsShattuck Labs,
Inc.InvestorRelations@Shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024